# DOD Duchenne Muscular Dystrophy, Clinical/Translational Research Award

Source: https://welltoldgrants.com/grants/ht942525dmdrpctra-dod-duchenne-muscular-dystrophy-clinical-translational/  
Official notice: https://www.grants.gov/search-results-detail/358798

> Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make about 6 awards worth $8.5 million in total. Applications closed on August 8, 2025.

| Field | Value |
|---|---|
| Opportunity number | HT942525DMDRPCTRA |
| Agency | Defense Health Agency Contracting Activity - DHACA |
| Status | Forecast |
| Deadline | August 8, 2025 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 6 |
| Total funding | $8.5 million |
| Cost sharing | not required |
| Assistance Listings | 12.420 |

## Who can apply

- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

## What the grant funds

Summary: The fiscal year 2025 (FY25) Duchenne Muscular Dystrophy Research Program (DMDRP) Clinical/Translational Research Award (CTRA) mechanism supports advanced translational research that will accelerate the movement of promising ideas in Duchenne muscular dystrophy (DMD) research into clinical applications. Research must address at least one of the FY25 CTRA focus areas. Research projects investigating therapies that will be efficacious across the life span, including infants, toddlers, and nonambulatory individuals, are strongly encouraged. Distinctive Features: Applications must include preliminary and/or published data relevant to DMD to support the proposed research project. Pilot, proof-of-principle clinical trials, and correlative studies to better inform development of drugs, devices, and other interventions are allowed. The CTRA offers two funding levels: Funding Level 1 to support smaller, less complex preclinical and/or clinical research; and Funding Level 2 to support larger, more complex preclinical and/or clinical research. Early-Career Partnering PI Option (PPIO): The Partnering PI must be an independent, early-career investigator within 10 years of their first faculty appointment (or equivalent) by the time of application submission. Lapses in research time or appointments as denoted in the biographical sketch should be explained in the application. It is encouraged, but not required, that the partnering PI is an M.D. or M.D./Ph.D. to increase collaboration between clinical and nonclinical aspects of DMD research.

## Questions people ask

### Is HT942525DMDRPCTRA still open?

No. It closed on August 8, 2025. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).

### Who can apply for DOD Duchenne Muscular Dystrophy, Clinical/Translational Research Award?

Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.

### What is the deadline for DOD Duchenne Muscular Dystrophy, Clinical/Translational Research Award?

Closed August 8, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

About $8.5 million in total across about 6 awards.

### Who has won Military Medical Research and Development grants before?

The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.